Browsing Tag
TScan Therapeutics
3 posts
TScan Therapeutics is cutting 75% of its workforce after starting Phase 3. What changed?
TScan Therapeutics has cut approximately three-quarters of its workforce, paused further enrolment in its Phase 3 ALLOHA-2 trial and removed both its chief financial officer and chief medical officer as it redirects its remaining capital toward in vivo cell therapy.
Does FDA clearance across three HLA subtypes de-risk TScan Therapeutics’ platform strategy?
FDA clears TSC-102-A01 and TSC-102-A03 for TScan Therapeutics. Explore how expanded HLA reach reshapes its heme cell therapy strategy.
TScan, Novartis to develop T cell receptor therapies for solid tumors
TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor…